Previous 10 | Next 10 |
2024-06-09 08:47:48 ET Summary Eli Lilly's tirzepatide shows potential in resolving metabolic dysfunction-associated steatohepatitis without worsening fibrosis. GLP-1 drugs pose a serious threat to Madrigal's Rezdiffra, potentially dominating the MASH market. Madrigal's financ...
2024-06-09 07:30:00 ET Structure Therapeutics (NASDAQ: GPCR) might have something cooking that could one day unseat the likes of Novo Nordisk 's (NYSE: NVO) Ozempic, a drug for type 2 diabetes, as well as its drug Wegovy, which is the same medicine but branded and indicated ...
2024-06-08 09:00:00 ET Odds are that if you hear the word "Ozempic," you likely associate that with weight loss. It's hard not to given all the posts on social media about users losing weight thanks to the drug. But many people may be surprised that it's not actually approved as a weight lo...
2024-06-07 10:53:19 ET More on Kroger Kroger: Downside Risk Mounts As Merger Poses Lose-Lose Scenario Kroger Deserves More Love Kroger: Albertsons Merger Creates Highly Skewed Return Potential (Technical Analysis) Kroger drivers at Michigan fulfillment center...
2024-06-06 07:00:00 ET The medicine for type 2 diabetes called Ozempic is, without a doubt, Novo Nordisk 's (NYSE: NVO) knight in shining armor. Thanks to an impressive amount of demand and the company's dedicated efforts in exploring other conditions that the medicine could potenti...
2024-06-05 13:44:31 ET More on LifeMD LifeMD: Moving Towards Profitability LifeMD, Inc. (LFMD) Q1 2024 Earnings Call Transcript LifeMD, Inc. 2024 Q1 - Results - Earnings Call Presentation LifeMD Q1 2024 Earnings Preview LifeMD Non-GAAP EPS of $0.15 be...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...
2024-06-04 14:57:26 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Novo Nordisk: The Market Is Right, Don't Fight Against It Eli Lilly sees...
2024-06-04 13:50:00 ET Summary More than 800 million people are estimated to be overweight or obese worldwide, and the growing prevalence of obesity, despite the availability of various treatments, suggests that isn’t going to change. The potential $500 billion market for G...
2024-06-04 09:53:00 ET Novo Nordisk 's (NYSE: NVO) type 2 diabetes drug Ozempic is a sensation, and it's no surprise why. In the first quarter, revenue from Ozempic rose 35% year over year to reach roughly $4.3 billion, and there's no sign of a slowdown in sight. In fact, it's v...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...